EOS 003 - Eos Therapies
Alternative Names: EOS-003 - Eos TherapiesLatest Information Update: 20 Dec 2024
Price :
$50 *
At a glance
- Originator Neuropore Therapies
- Class Antiparkinsonians; Small molecules
- Mechanism of Action Toll-like receptor 2 antagonists; Toll-like receptor 9 antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Neurodegenerative disorders; Parkinson's disease
Most Recent Events
- 20 Dec 2024 EOS 003 - Eos Therapies is available for licensing as of 25 Nov 2024. info@eostherapies.com
- 20 Dec 2024 Eos Therapies plans a clinical trial for Neurodegenerative or Peripheral inflammatory disorders in late 2025
- 25 Nov 2024 Eos therapies acquires EOS 003 from Neuropore Therapies, prior to November 2024